News | December 06, 2024
Eugia Pharma receives USFDA approval for Pazopanib Tablets, 200 mg
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
The approved product has an estimated market size of US$ 106 million for the twelve months ending October 2024, according to IQVIA
Granules has undertaken a proactive, voluntary and comprehensive remediation plan to address the six form 483 observations raised by the USFDA
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy
If approved, Blenrep (belantamab mafodotin) in combinations with BorDex (BVd) and PomDex (BPd) could redefine multiple myeloma treatment at or after first relapse
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Emcure has launched an awareness campaign to help spread the word about male anemia
Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years
Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
Subscribe To Our Newsletter & Stay Updated
